Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 18 to ≤ 37 kg/m\^2~* Clinical diagnosis of chronic HCV infection defined by positive serology for HCV for at least 6 months and detectable HCV RNA in peripheral blood ≥105 IU/mL at screening~* Participant must be infected with HCV GT1a, GT1b, or GT 3~Exclusion Criteria:~* Co-infection with GT1 and GT3~* Estimated creatinine clearance of ≤70 mL/min based on the Cockcroft-Gault equation~* History of stroke, chronic seizures, or major neurological disorder~* History of clinically significant endocrine, gastrointestinal (excepting HCV infection), cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* History of neoplastic disease~* Positive Hepatitis B surface antigen at the pre-study (screening) visit~* Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior to the prestudy (screening) visit.~* Previous treatments (s) with nonstructural protein 5A (NS5A) inhibitors~* \<4 weeks since administration of any experimental protease inhibitor~* Previous exposure to interferon-alpha and/or ribavirin within 3 month prior to the first dose of elbasvir in the study~* Clinical or laboratory evidence of advanced or decompensated liver disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- GT1 HCV 10-mg Elbasvir (Panel A) (Type: EXPERIMENTAL): Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
- GTI HCV 50-g Elbasvir (Panel B) (Type: EXPERIMENTAL): Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
- GT1 HCV 5-mg Elbavir (Panel C) (Type: EXPERIMENTAL): Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
- GT1 HCV 200-mg Elbasvir (Panel D) (Type: EXPERIMENTAL): Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
- GT3 HCV 10-mg Elbasvir (Panel E) (Type: EXPERIMENTAL): Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
- GT3 HCV 50-mg Elbasvir (Panel F) (Type: EXPERIMENTAL): Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
- GT3 HCV 100-mg Elbasvir (Panel G) (Type: EXPERIMENTAL): Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
- GT3 HCV 200-mg Elbasvir (Panel H) (Type: EXPERIMENTAL): Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
- GT1a HCV 10-mg Elbasvir (Panel I) (Type: EXPERIMENTAL): Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
- GT1a HCV 50-mg Elbasvir (Panel J) (Type: EXPERIMENTAL): Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete